MedTrace Logo

Study of the AL3810 in the Treatment of Advanced Solid Tumor

NCT03117101 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-04-17

No results posted yet for this study

Summary

This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study

Conditions

Interventions

DRUG

Lucitanib

Sponsors & Collaborators

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences

    collaborator OTHER

  • Haihe Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jin Li, M.D. · Fudan University

  • Junning Cao, M.D. · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03117101 on ClinicalTrials.gov